AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

5 stories found

Paper-cut diagnostic panels and a clinician's hand suggest careful evaluation of imaging AI.
Social good & healthGlobal+1 clusters01

Medical AI has promising signals. Patients need proof of benefit.

These are results worth taking seriously—not because they settle the case for medical AI, but because they make the next questions sharper. A fracture-detection umbrella review covered 50 reviews and 387 primary studies. Its pooled sensitivity was 89.7% and specificity 90.4%, but certainty was generally low or very low. Comparisons between clinicians, standalone AI and assisted clinicians remained inconclusive. No included review reported adverse events or other safety outcomes. That is missing evidence, not a clean bill of health. A separate BREST-AI study examined three-year breast-cancer risk from negative screening mammograms. In external UK case–control validation, its AUC was 0.751 versus 0.700 for Mirai. The smaller US comparison did not demonstrate a statistically significant improvement. AUC measures ranking performance across thresholds; 0.751 does not mean that 75.1% of women received a correct diagnosis. The promise is real enough to investigate. Better risk stratification might help target follow-up, while better fracture detection might help clinicians notice an injury. But a useful score becomes a useful service only through decisions: who gets another examination, who waits, who receives reassurance and who is exposed to unnecessary procedures. NICE's conditional approach to certain fracture tools offers a practical model: use as an adjunct while gathering evidence, rather than substituting software for definitive review. These two new papers do not establish reduced mortality or safer care. They tell us where to look next, and which outcomes deserve to decide whether a promising tool earns a lasting place.

3 min
A luminous glass examination lens connects a small clinic with an amber human figure.
Social good & healthUnited States / China+1 clusters02

Medical AI can matter before it becomes a better doctor

There is something worth celebrating in an AI system that helps a person actually get a test. Two new Nature Communications studies focus attention on access and the practical work of acquiring medical information, rather than a sweeping claim that software replaces clinicians. That is a useful change of emphasis. The ACCESS2 study examined point-of-care autonomous diabetic-eye screening in 397 young people with diabetes. Screening completion reached 99.5% among White participants and 98% among non-White participants, compared with lower and more unequal prior completion. Those are encouraging access results. They do not establish that treatment was received or vision improved. The reported 100% sensitivity also has a wide 95% confidence interval of 67.6–100%; it should not be presented as diagnostic perfection. Specificity was 76%, so the downstream assessment pathway matters. A separate study evaluated an AI-guided, patient-mounted ultrasound system in 102 healthy participants and 17 patients. Its 588-gram figure describes the end-effector, not necessarily the entire system. The authors report interpretable liver images and promising acquisition performance, including field-oriented demonstrations. This is feasibility evidence, not proof that a portable robot can replace an experienced clinician across settings. The shared opportunity is concrete: reduce the distance between someone and a useful examination. My appreciation comes with a practical condition. A positive screen needs confirmation, an explanation and access to care. If the test arrives but the referral pathway does not, we may move the bottleneck rather than remove it. Still, making the first step easier is real progress worth investigating—not a consolation prize for failing to automate the whole profession.

4 min
Cognition & learningGlobal+3 clusters03

Hu et al., “A scoping review of explainable artificial intelligence for medical multimodal data”

University of Sydney and UC San Diego researchers reviewed 82 studies combining medical imaging, clinical records, and other health-data modalities. They find that most explanations still assign importance to each modality separately and rely on post-hoc techniques that leave the model’s cross-modal reasoning opaque; standardized evaluation was absent from most studies, qualitative assessment predominated, and only a minority provided sufficiently reproducible public code.

2 min
A researcher examines imaging slices with warm brown-fat signals while a separate mouse study remains in the background.
Social good & healthUnited States+2 clusters04

AI helped map brown fat in thousands of scans. The drug clue is not a cure.

An existing blood-pressure medicine has become an intriguing candidate in brown-fat research, but the evidence has not crossed into a human treatment claim. In a peer-reviewed Nature study, researchers analyzed imaging and records from 101,243 patients at a large cancer center. Brown fat, which spends energy producing heat, was associated with lower prevalence of several cardiovascular and psychiatric diagnoses. Machine learning allowed the team to semi-automatically quantify brown-fat activity in roughly 8,700 patients. Higher activity, particularly in one underarm depot, correlated with lower odds of cardiometabolic disease and a healthier distribution of white fat. Medication records then pointed to a class of blood-pressure drugs. Follow-up tests found that losartan increased brown-fat cell activity and energy expenditure in mice. That sequence matters: the AI analysis helped move from a broad clinical pattern to a specific, experimentally testable mechanism. It also sets a firm boundary. These patients were not randomized to change brown-fat activity; they were drawn from a cancer center; and the losartan result was not a trial showing improved human outcomes. The NIH describes it as a possible route to future drug repurposing, not a current indication. Patients should not alter medication because of a headline. The next evidence should be replication in other populations and prospective testing that measures patient outcomes, dosage and adverse effects. The real success of AI here is accelerating a scientific question without pretending the answer is finished.

6 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters05

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min